H.C. Wainwright Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $35

Moomoo NewsJan 8 07:34 ET · Ratings

Stoke Therapeutics' Promising Potential: Buy Rating Backed by Strong Phase 3 Trial Design and Positive Early Results

TipRanksJan 8 07:16 ET · Ratings

Stoke Therapeutics Analyst Ratings

BenzingaJan 8 06:34 ET · Ratings

Stoke Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Stoke TherapeuticsJan 8 00:00 ET

Chardan Capital Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $24

Moomoo NewsJan 7 18:31 ET · Ratings

Stoke Therapeutics Negative Reaction After STK-001 Update Overdone, Says Chardan

TipRanksJan 7 17:30 ET